Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Longer-term "maintenance" therapy may be the new frontier for oncology products as cancer evolves into a chronic, manageable disease – a shift that will provide benefits for patients and the pharmaceutical industry. But as cancer drug costs continue to skyrocket and cost-effectiveness discussions become more commonplace, that transition may not come as smoothly as industry would like.
You may also be interested in...
ASCO Leaders Endorse Long-Term Use Of Revlimid And Rituxan To Prevent Relapse
Preview of upcoming American Society of Clinical Oncology conference highlights strong progression-free survival results, but overall survival benefit remains to be proven.
Regulatory Updates, In Brief
At last, Novartis' everolimus approved for kidney transplant: FDA approved Novartis' mTOR inhibitor everolimus April 20 for its originally proposed organ transplant setting, as part of an immunosuppressive regimen to prevent rejection in low-to-moderate risk kidney transplant patients. Key to the proliferation inhibitor's approval is the cyclosporine-sparing regimen in which it was tested. Cyclosporine is toxic to kidneys and has been linked to increased risk of infection and malignant tumors. Everolimus, branded Zortress in the U.S. (and marketed as Certican abroad), is to be used in combination with cyclosporine, basiliximab (Novartis' Simulect) and corticosteroids. The approval comes with a Risk Evaluation and Mitigation Strategy that includes a Medication Guide, a communications plan and a timetable for assessments (1"The Pink Sheet" DAILY, Dec. 7, 2009). Though everolimus was cleared in March 2009 as Afinitor to treat advanced renal cell carcinoma and in July 2008 as part of Abbott's drug-eluting Xcience stent, the transplant indications for which Novartis originally aimed had remained elusive. The drug was turned down for use in heart transplants by FDA advisors in 2005, following on "approvable" letters in 2003 and 2004. A resubmission for heart transplantation can't be far away, however. Data from a U.S. Phase III study in heart transplant are expected in 2011, and a global Phase III liver transplant study is ongoing
U.K.'s Controversial NICE Suspends Publication Of Guidances Until After General Election
Its favorable recommendation of Alimta as maintenance therapy in lung cancer patients is the last before the U.K. election on May 6.